• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form S-1/A filed by Know Labs Inc.

    7/24/24 9:49:42 PM ET
    $KNW
    Industrial Machinery/Components
    Industrials
    Get the next $KNW alert in real time by email
    S-1/A 1 knwn_s1a.htm FORM S-1/A knwn_s1a.htm

    As filed with the Securities and Exchange Commission on July 24, 2024

     

    Registration No. 333‑280273

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D. C. 20549

     

    Amendment No. 4 to

     

    FORM S‑1

     

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    Know Labs, Inc.

    (Exact name of registrant as specified in its charter)

     

    Nevada

     

    3920

     

    90‑0273142

    (State or other jurisdiction of

    incorporation or organization)

     

    (Primary Standard Industrial

    Classification Code Number)

     

    (IRS Employer

    Identification No.)

     

    619 Western Avenue, Suite 610

    Seattle, Washington 98104

    206‑903‑1351

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     

    Ronald P. Erickson

    Chief Executive Officer

    619 Western Avenue, Suite 610

    Seattle, Washington 98104

    206‑903‑1351

    (Names, address, including zip code and telephone number, including area code, of agent for service)

     

    Copies to:

     

    Joshua E. Little

    Dentons Durham Jones Pinegar P.C.

    192 East 200 North, 3rd Floor

    St. George, UT 84770

    (435) 674-0400

    [email protected]

    Cavas Pavri

    ArentFox Schiff LLP

    1717 K Street NW

    Washington, DC 20006

    Phone: (202) 724-6847

    Fax: (202)857-6395

     

    Approximate date of commencement of proposed sale to the public: As soon as practicable after this registration statement is declared effective.

     

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☒

     

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    If this Form is a post‑effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    If this Form is a post‑effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non‑accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b‑2 of the Exchange Act.

     

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

    Non‑accelerated filer

    ☒

    Smaller reporting company

    ☒

     

     

    Emerging growth company

    ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

    The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Securities and Exchange Commission acting pursuant to such Section 8(a), may determine.

     

     

     

     

    EXPLANATORY NOTE

     

    Know Labs, Inc. (the “Company”) is filing this Amendment No. 4 (this “Amendment”) to its Registration Statement on Form S-1 (File No. 333-280273) (the “Registration Statement”) as an exhibits-only filing, solely to file Exhibit 23.1. Accordingly, this Amendment consists only of the facing page, this explanatory note, Item 16(a) of Part II of the Registration Statement, the signature page to the Registration Statement and the filed exhibits. The remainder of the Registration Statement is unchanged and has therefore been omitted.

     

     
    2

     

     

    PART II

     

    INFORMATION NOT REQUIRED IN THE PROSPECTUS

     

    Item 16. Exhibits.

     

    (a) Exhibits.

     

    Exhibit No.

     

    Description

    1.1**

    Form of Underwriting Agreement

    3.1

     

    Restatement of the Articles of Incorporation, dated August 11, 2023 (incorporated by reference to the Company’s Current Report on Form 8-K, field August 14, 2023)

    3.2

     

    Second Amended and Restated Bylaws, dated October 15, 2021 (incorporated by reference to the Company’s Current Report on Form 8‑K, filed December 7, 2021)

    3.3

     

    Amended and Restate Series C Certificate of Designation, dated August 11, 2023 (incorporated by reference to the Company’s Current Report on Form 8-K filed August 14, 2023)

    3.4

     

    Third Amended and Restated Series D Certificate of Designation, dated August 11, 2023 (incorporated by reference to the Company’s Current Report on Form 8-K filed August 14, 2023)

    3.5

     

    Series D Certificate of Correction of Know Labs, Inc., dated August 11, 2023 (incorporated by reference to the Company’s Current Report on Form 8-K filed August 14, 2023)

    3.6

     

    Series C Certificate of Correction of Know Labs, Inc., dated August 11, 2023 (incorporated by reference to the Company’s Current Report on Form 8-K filed August 14, 2023)

    3.7

     

    Certificate of Withdrawal of Series F Preferred Stock, dated August 11, 2023 (incorporated by reference to the Company’s Current Report on Form 8-K filed August 14, 2023)

    3.8

     

    Certificate of Designation of Series F Preferred Stock (incorporated by reference to the Company’s Current Report on Form 8‑K, filed August 3, 2018)

    4.1†

     

    Know Labs, Inc. 2021 Equity Incentive Plan (incorporated by reference to the Company’s Form S‑8 Filed December 10, 2021)

    4.2**

     

    Form of Unit Purchase Option

    4.3**

     

    Form of Warrant included in the Units

    4.4**

     

    Warrant Agency Agreement

    5.1**

     

    Opinion of Dentons Durham Jones Pinegar P.C.

    10.1

     

    Form of Preferred Stock and Warrant Purchase Agreement, Form of Amended and Restated Registration Rights Agreement. and Form of Series F Warrant to Purchase common stock by and between Visualant, Incorporated and Clayton A. Struve (incorporated by reference to the Company’s Current Report on Form 8-K, filed May 5, 2017)

    10.2

     

    Securities Purchase Agreement dated August 14, 2017 by and between Visualant, Incorporated and accredited investor (incorporated by reference to the Company’s Current Report on Form 8-K, filed August 18, 2017)

    10.3

     

    Senior Secured Convertible Redeemable Debenture dated December 12, 2017 by and between Visualant, Incorporated and accredited investor. (incorporated by reference to the Company’s Current Report on Form 8-K, filed December 22, 2017)

    10.4

     

    Senior Secured Convertible Redeemable Debenture dated February 28, 2018 by and between Visualant, Incorporated and accredited investor. (incorporated by reference to the Company’s Current Report on Form 8-K, filed March 7, 2018)

    10.5

     

    Note and Account Payable Conversion Agreement and related notes and warrants dated January 31, 2018 by and between Visualant, Incorporated and J3E2A2Z LP (incorporated by reference to the Company’s Current Report on Form 8-K, filed March 21, 2018)

    10.8†

     

    Amended Employment Agreement dated April 10, 2018 by and between Visualant, Incorporated and Ronald P. Erickson. (incorporated by reference to the Company’s Annual Report on Form 10-K, filed December 21, 2018)

     

     
    3

     

     

    10.9†

     

    Employment Agreement dated May 13, 2022 by and between Know Labs, Inc. and Peter Conley. (incorporated by reference to the Company’s Quarterly Report on Form 10-Q, filed August 12, 2022)

    10.11

     

    Common Stock Purchase Warrant issued by Know Labs, Inc. to Boustead Securities, LLC on September 20, 2022 (incorporated by reference to the Company’s Current Report on Form 8-K, filed September 21, 2022)

    10.12

     

    Extension of Warrant Agreement dated December 7, 2022 by and between Know Labs, Inc. and Clayton A. Struve (incorporated by reference to the Company’s Current Report on Form 8-K, filed December 9, 2022)

    10.13

     

    Extension of Warrant Agreement dated January 19, 2023 by and between Know Labs, Inc. and Ronald P. Erickson (incorporated by reference to the Company’s Current Report on Form 8-K, filed January 23, 2023).

    10.14

     

    Extension of Warrant Agreement dated January 19, 2023 by and between Know Labs, Inc. and J3E2A2Z LP (incorporated by reference to the Company’s Current Report on Form 8-K, filed January 23, 2023).

    10.15

     

    Amendment 10 dated September 15, 2023 to Convertible Redeemable Promissory Note dated January 31, 2018, by and between Know Labs, Inc. and J3E2A2Z LP (incorporated by reference to the Company’s Current Report on Form 8-K, filed September 19, 2023).

    10.16

     

    Amendment 10 dated September 15, 2023 to Convertible Redeemable Promissory Note dated January 31, 2018, by and between Know Labs, Inc. and J3E2A2Z LP (incorporated by reference to the Company’s Current Report on Form 8-K, filed September 19, 2023).

    10.17

     

    Amendment 9 dated September 15, 2023 to Senior Secured Convertible Redeemable Note dated September 30, 2016 by and between Know Labs, Inc. and Clayton A. Struve (incorporated by reference to the Company’s Current Report on Form 8-K, filed September 19, 2023).

    10.18

     

    Amendment 9 dated September 15, 2023 to Senior Secured Convertible Redeemable Note dated August 14, 2017 by and between Know Labs, Inc. and Clayton A. Struve (incorporated by reference to the Company’s Current Report on Form 8-K, filed September 19, 2023).

    10.19

     

    Amendment 9 dated September 15, 2023 to Senior Secured Convertible Redeemable Note dated December 12, 2017 by and between Know Labs, Inc. and Clayton A. Struve (incorporated by reference to the Company’s Current Report on Form 8-K, filed September 19, 2023).

    10.20

    Amendment 8 dated September 15, 2023 to Senior Secured Convertible Redeemable Note dated February 28, 2018 by and between Know Labs, Inc. and Clayton A. Struve (incorporated by reference to the Company’s Current Report on Form 8-K, filed September 19, 2023).

    10.21

    Underwriting Agreement, dated September 26, 2023, between Know Labs, Inc., Boustead Securities, LLC and The Benchmark Company, LLC (incorporated by reference to the Company’s Current Report on Form 8-K, filed September 29, 2023).

    10.22

     

    Common Stock Purchase Warrant issued by Know Labs, Inc. to Boustead Securities, LLC on September 29, 2023 (incorporated by reference to the Company’s Current Report on Form 8-K, filed September 29, 2023).

    10.23

     

    Common Stock Purchase Warrant issued by Know Labs, Inc. to The Benchmark Company, LLC on September 29, 2023 (incorporated by reference to the Company’s Current Report on Form 8-K, filed September 29, 2023).

    10.24

     

    Securities Purchase Agreement, dated February 27, 2024, between Know Labs, Inc. and Lind Global II, LP (incorporated by reference to the Company’s Current Report on Form 8-K, filed February 29, 2024).

    10.25

     

    Form of Convertible Secured Promissory Note issued by Know Labs, Inc. to Lind Global II, LP on February 27, 2024 (incorporated by reference to the Company’s Current Report on Form 8-K, filed February 29, 2024).

    10.26

     

    Form of Warrant to Purchase Common Stock issued by Know Labs, Inc. to Lind Global II, LP on February 27, 2024 (incorporated by reference to the Company’s Current Report on Form 8-K, filed February 29, 2024).

    10.27

     

    Security Agreement, dated February 27, 2024, between Know Labs, Inc. and Lind Global II, LP (incorporated by reference to the Company’s Current Report on Form 8-K, filed February 29, 2024).

    10.28

     

    Guaranty, dated February 27, 2024, between Know Labs, Inc. and Lind Global II, LP (incorporated by reference to the Company’s Current Report on Form 8-K, filed February 29, 2024).

    10.29

     

    At the Market Offering Agreement, dated March 20, 2024, by and between Know Labs, Inc. and The Benchmark Company, LLC (incorporated by reference to the Company’s Current Report on Form 8-K, filed March 20, 2024).

    14.1

     

    Code of Ethics dated November 2018 (incorporated by reference to the Company’s Current Report on Form 8‑K, filed November 27, 2018)

    21.1

     

    Subsidiaries of the Registrant. (incorporated by reference to the Company’s Annual Report on Form 10-K, filed December 19, 2023)

    23.1*

     

    Consent of BPM LLP, Independent Registered Public Accounting Firm

    23.2**

     

    Consent of Dentons Durham Jones Pinegar P.C. (included in Exhibit 5.1)

    24.1**

     

    Power of Attorney (included in the signature page)

    99.1

     

    Audit Committee Charter dated November 2018 (incorporated by reference to the Company’s Current Report on Form 8-K, filed November 27, 2018)

    99.2

     

    Compensation Committee Charter dated November 2018 (incorporated by reference to the Company’s Current Report on Form 8-K, filed November 27, 2018)

    99.3

     

    Nominations and Corporate Governance Committee Charter dated November 2018 (incorporated by reference to the Company’s Current Report on Form 8-K, filed November 27, 2018)

    107**

     

    Exhibit Filing Fees

    ___________________

    †

    Executive compensation plan or arrangement.

    *

    Filed herewith.

    **

    Previously filed.

     

     
    4

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Seattle, State of Washington, on July 24, 2024.

     

    Know Labs, Inc.

     

     

     

    By:

    /s/ Ronald P. Erickson

     

     

     

    Ronald P. Erickson

    Chief Executive Officer and Director

     

     

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature

     

    Title

     

    Date

     

     

     

     

     

    /s/ Ronald P. Erickson

     

    Chief Executive Officer

     

    July 24, 2024

    Ronald P. Erickson

     

    (Principal Executive Officer), Director

     

     

     

     

     

     

     

    *

     

    Chief Financial Officer

     

    July 24, 2024

    Peter Conley

     

    (Principal Financial and Accounting Officer)

     

     

     

     

     

     

     

    *

     

    Director

     

    July 24, 2024

    Jon Pepper

     

     

     

     

     

     

     

     

     

    *

     

    Director

     

    July 24, 2024

    William A. Owens

     

     

     

     

     

     

     

     

     

    *

     

    Director

     

    July 24, 2024

    Ichiro Takesako

     

     

     

     

     

     

     

     

     

    *

     

    Director

     

    July 24, 2024

    John Cronin

     

     

     

     

     

     

     

     

     

    *

     

    Director

     

    July 24, 2024

    Timothy Londergan

     

     

     

     

     

     

     

     

     

    *

     

    Director

     

    July 24, 2024

    Larry K. Ellingson

     

     

     

     

     

    *

    By:

    /s/ Ronald P. Erickson

     

    Name: Ronald P. Erickson 

     

     

    Title: Attorney-in-fact

     

     

     

     
    5

     

    Get the next $KNW alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KNW

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $KNW
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Greg Kidd to Acquire Controlling Interest in Know Labs and Introduce Bitcoin Treasury Strategy

      Know Labs, Inc. (NYSE American: KNW ("Know Labs" or the "Company"), a technology innovator specializing in non-invasive health monitoring solutions, today announced that it has entered into an agreement with Goldeneye 1995 LLC ("Buyer"), an affiliate of fintech investor, entrepreneur, and former Ripple Chief Risk Officer, Greg Kidd, to acquire a controlling interest in the Company. Upon the closing of the transaction, Mr. Kidd will become Chief Executive Officer and Chairman of the Board of Directors of the Company. Under the terms of the agreement, the Buyer will acquire that number of shares of the Company's common stock obtained by dividing (i) the sum of 1,000 Bitcoin and a cash sum t

      6/6/25 9:00:00 AM ET
      $KNW
      Industrial Machinery/Components
      Industrials
    • Know Labs Sensor Non-Invasively Identifies pH Levels in Real Time

      Significant Applications in Health Care, Food Quality and Safety and More Know Labs, Inc. (NYSE:KNW) is pleased to announce that it has completed extensive research in its laboratory utilizing its patented Radio Frequency Dielectric Spectroscopy (RFDS) sensor technology to identify changes in pH levels in real time. The research has been submitted for peer reviewed publication. The research is available for review today here on the Company's website at www.knowlabs.co. An abstract of the paper states, "We describe an experiment in which we employ a radio frequency sensor to measure pH changes in a liquid solution. The experiment is novel in a few ways. First, the sensor does not have cont

      3/19/25 9:00:00 AM ET
      $KNW
      Industrial Machinery/Components
      Industrials
    • Know Labs to Attend the 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)

      The company to meet with potential strategic partners to discuss collaborating on advancing clinical research of its non-invasive blood glucose monitor Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology with its Radio Frequency Dialectic Spectroscopy (RFDS) platform, today announced the company will be attending The 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) Technology Fair in Amsterdam, Netherlands on March 19-22, 2025. The Company will share updates on the development of its non-invasive blood glucose monitor, since last year's conference, and discuss opportunities for collaboration and partnership

      3/18/25 9:00:00 AM ET
      $KNW
      Industrial Machinery/Components
      Industrials

    $KNW
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by CEO Erickson Ronald P

      4 - KNOW LABS, INC. (0001074828) (Issuer)

      6/4/25 4:15:21 PM ET
      $KNW
      Industrial Machinery/Components
      Industrials
    • Director Takesako Ichiro John Paul was granted 25,000 shares, increasing direct ownership by 645% to 28,875 units (SEC Form 4)

      4 - KNOW LABS, INC. (0001074828) (Issuer)

      5/7/25 4:16:32 PM ET
      $KNW
      Industrial Machinery/Components
      Industrials
    • Director Ellingson Larry K was granted 25,000 shares, increasing direct ownership by 6,188% to 25,404 units (SEC Form 4)

      4 - KNOW LABS, INC. (0001074828) (Issuer)

      5/7/25 4:16:34 PM ET
      $KNW
      Industrial Machinery/Components
      Industrials

    $KNW
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Know Labs Inc. (Amendment)

      SC 13D/A - KNOW LABS, INC. (0001074828) (Subject)

      6/3/24 2:11:39 PM ET
      $KNW
      Industrial Machinery/Components
      Industrials
    • SEC Form SC 13D filed by Know Labs Inc.

      SC 13D - KNOW LABS, INC. (0001074828) (Subject)

      10/25/23 7:27:11 PM ET
      $KNW
      Industrial Machinery/Components
      Industrials
    • SEC Form SC 13D/A filed by Know Labs Inc. (Amendment)

      SC 13D/A - KNOW LABS, INC. (0001074828) (Subject)

      10/19/23 6:32:18 AM ET
      $KNW
      Industrial Machinery/Components
      Industrials

    $KNW
    Leadership Updates

    Live Leadership Updates

    See more
    • Know Labs Appoints Chris Somogyi as President, International

      Somogyi to lead Know Labs' "Skunkworks" Program and drive global revenues. Know Labs, Inc. (NYSE:KNW), an emerging leader in non-invasive medical diagnostic technology, today announced the appointment of Chris Somogyi as President, International. With over 40 years of experience in commercializing innovation across related industries, Somogyi brings a wealth of expertise to lead the Company's "Skunkworks" Program and global patent licensing efforts. In his role, Somogyi will focus on identifying new applications of Know Labs' extensive intellectual property (IP) portfolio consisting of over 300 patents issued, pending and in-process and covering more than 100 medical and non-medical app

      5/16/24 9:00:00 AM ET
      $KNW
      Industrial Machinery/Components
      Industrials
    • Know Labs Expands Medical and Scientific Advisory Board

      New Members Bring Extensive Clinical Diabetes Management and FDA Expertise Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the appointment of four new members to the Company's Medical and Scientific Advisory Board. The new additions to the Advisory Board are Jeff Hitchcock, Karmeen Kulkarni, Dr. Meng Tan and Dr. Satish Garg. They bring to the board extensive experience in clinical diabetes management, including the advancement of new technologies and innovation in medical diagnostics. The Medical and Scientific Advisory Board is chaired by Know Labs' Chief Medical Officer, Dr. James H. "Andy" Anderson. The Advisory Board p

      12/14/23 9:00:00 AM ET
      $KNW
      Industrial Machinery/Components
      Industrials
    • Know Labs Expands Board of Directors

      Appoints Three New Directors with Deep Sector Expertise Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the appointment of three new members to the Company's Board of Directors. These appointments increase the number of Directors to seven. Each new Director brings to the board extensive sector-relevant experience with deep knowledge of the science and the marketplace that is the focus of Know Labs. The new appointees are John Cronin, Larry Ellingson and Tim Londergan. John Cronin is the founder and CEO of ipCapital Group, Inc., a leading global advisory company on intellectual property strategy and monetization. Cronin beg

      11/8/23 9:00:00 AM ET
      $KNW
      Industrial Machinery/Components
      Industrials

    $KNW
    Financials

    Live finance-specific insights

    See more
    • Know Labs, Inc. Reports Third Quarter FY2023 Results

      Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the third quarter ended June 30, 2023. Financial Highlights: Know Labs reported a net loss of $3.59 million dollars in the third quarter of 2023, compared to a net loss of $3.03 million dollars in the year-ago period, which translates to Earnings Per Share of a loss of $0.07, unchanged from the year ago period of a loss of $0.07 before preferred stock dividends. Recorded a non-cash charge to earnings of $4.96 million related to the fair market value of dividends on the Company's Series C and D preferred stock, that were either paid or accrued in share

      8/14/23 4:15:00 PM ET
      $KNW
      Industrial Machinery/Components
      Industrials
    • Know Labs, Inc. Reports Second Quarter FY2023 Results

      Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the second quarter ended March 31, 2023. Financial Highlights: Know Labs reported a net loss of $4.93 million dollars in the second quarter of 2023, compared to a net loss of $6.14 million dollars in the year-ago period, which translates to Earnings Per Share of a loss of $0.10, an improvement over the year ago period of a loss of $0.16. Research and development expense for the second quarter was $2.56 million dollars as compared to $1.25 million dollars in 2022. The increase in R&D expense was related to staff increases in engineering, third party te

      5/15/23 4:05:00 PM ET
      $KNW
      Industrial Machinery/Components
      Industrials
    • Know Labs, Inc. Reports First Quarter 2023 Results

      Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the first quarter ended December 31, 2022. Financial Highlights: Know Labs reported a net loss of $3.82 million in the first quarter of 2023, compared to a net loss of $5.36 million in the first quarter of 2022, which translates to Earnings Per Share of a loss of $0.08 versus a loss of $0.15 in the year ago period. Research and development expense for the first quarter ended December 31, 2022, was $1.74 million as compared to $886,000 in the same year ago period. The increase in R&D expense was related to staff increases in engineering, third party techn

      2/14/23 4:00:00 PM ET
      $KNW
      Industrial Machinery/Components
      Industrials

    $KNW
    SEC Filings

    See more
    • Know Labs Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - KNOW LABS, INC. (0001074828) (Filer)

      6/6/25 9:00:35 AM ET
      $KNW
      Industrial Machinery/Components
      Industrials
    • Know Labs Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Financial Statements and Exhibits

      8-K - KNOW LABS, INC. (0001074828) (Filer)

      6/4/25 5:07:06 PM ET
      $KNW
      Industrial Machinery/Components
      Industrials
    • SEC Form 10-Q filed by Know Labs Inc.

      10-Q - KNOW LABS, INC. (0001074828) (Filer)

      5/14/25 4:24:08 PM ET
      $KNW
      Industrial Machinery/Components
      Industrials